martedì, 5 maggio 2026

Notizie AIOM – anno XVII

ASCO Launches Task Force to Address the Cancer Care Gap in Rural America

June 25, 2019 - Despite progress being made in cancer survivorship - there are currently nearly 17 million cancer survivors in the United States - not everyone is benefiting equally, especially those patients living in rural communities across America. According to “The ...
Leggi tutto

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 24, 2019 - The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors ...
Leggi tutto

FDA Approves Newly Designed Syringe for Lanreotide in GEP-NETs

June 24, 2019 - The FDA has granted an approval to a prefilled syringe for lanreotide, which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced ...
Leggi tutto

One additional country to benefit from EU-US mutual recognition agreement for inspections

June 27, 2019 - On 26 June 2019, Germany was included into the mutual recognition agreement between the European Union and the United States Food and Drug Administration (FDA). The FDA thus confirmed the capability of this additional EU Member State to carry out good manufacturing ...
Leggi tutto

28 giugno 2019 – Registro Sonidegib (Novartis) – Attivazione web e pubblicazione schede di monitoraggio

FDA Approves Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

June 27, 2019 - The FDA has approved the combination of daratumumab with lenalidomide and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT). The approval, which was granted ...
Leggi tutto

24 giugno 2019 – Nota Informativa Importante su biotina

24 giugno 2019 – Comunicazione EMA su medicinali contenenti leuprorelina

FDA Grants Priority Review to Niraparib for Late-Stage Ovarian Cancer

June 24, 2019 - The FDA has granted a priority review designation to a supplemental biologics license application for niraparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 or more prior ...
Leggi tutto

Talazoparib Approved in Europe for BRCA-Mutant Breast Cancer

June 21, 2019 - The European Commission has approved single-agent talazoparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. The approval is based on findings from the phase III EMBRACA study, ...
Leggi tutto